Treatment options include lifestyle changes, medications, a number of procedures, and surgery.[1][2] In those with mild symptoms, weight loss, exercise, and decreasing
caffeine intake are recommended, although the quality of the evidence for exercise is low.[2][4] In those with more significant symptoms, medications may include
alpha blockers such as
terazosin or
5α-reductase inhibitors such as
finasteride.[1] Surgical removal of part of the prostate may be carried out in those who do not improve with other measures.[2] Some
herbal medicines that have been studied, such as
saw palmetto, have not been shown to help.[2] Other herbal medicines somewhat effective at improving urine flow include
beta-sitosterol[5] from Hypoxis rooperi (African star grass),
pygeum (extracted from the bark of Prunus africana),[6] pumpkin seeds (Cucurbita pepo), and
stinging nettle (Urtica dioica) root.[7]
About 105 million men are affected globally.[3] BPH typically begins after the age of 40.[1] Half of males age 50 and over are affected.[2] After the age of 80, that figure climbs to as high as about 90% of males affected.[8][9][1] Although
prostate specific antigen levels may be elevated in males with BPH, the condition does not increase the risk of
prostate cancer.[10]
Signs and symptoms
BPH is the most common cause of
lower urinary tract symptoms (LUTS), which are divided into storage,
voiding, and symptoms which occur after urination.[11] Storage symptoms include the need to urinate frequently,
waking at night to urinate,
urgency (compelling need to void that cannot be deferred),
involuntary urination, including involuntary urination at night, or
urge incontinence (urine leak following a strong sudden need to urinate).[12] Voiding symptoms include
urinary hesitancy (a delay between trying to urinate and the flow actually beginning), intermittency (not continuous),[13] involuntary interruption of voiding, weak urinary stream, straining to void, a sensation of incomplete emptying, and uncontrollable leaking after the end of urination.[14][15][16] These symptoms may be accompanied by bladder pain or pain while urinating, called
dysuria.[17]
Bladder outlet obstruction (BOO) can be caused by BPH.[18] Symptoms are abdominal pain, a continuous feeling of a full bladder, frequent urination, acute urinary retention (inability to urinate), pain during urination (dysuria), problems starting urination (urinary hesitancy), slow urine flow, starting and stopping (urinary intermittency), and nocturia.[19]
BPH can be a progressive disease, especially if left untreated. Incomplete voiding results in residual urine or urinary stasis, which can lead to an increased risk of
urinary tract infection.[20]
Causes
Hormones
Most experts consider
androgens (
testosterone and related
hormones) to play a permissive role in the development of BPH. This means that androgens must be present for BPH to occur, but do not necessarily directly cause the condition. This is supported by evidence suggesting that
castrated boys do not develop BPH when they age. In an unusual study of 26
eunuchs from the palace of the
Qing dynasty still living in
Beijing in 1960, the prostate could not be felt in 81% of the studied eunuchs.[21] The average time since castration was 54 years (range, 41–65 years). On the other hand, some studies suggest that administering exogenous testosterone is not associated with a significant increase in the risk of BPH symptoms, so the role of testosterone in prostate cancer and BPH is still unclear. Further randomized controlled trials with more participants are needed to quantify any risk of giving exogenous testosterone.[22]
Dihydrotestosterone (DHT), a
metabolite of testosterone, is a critical mediator of prostatic growth. DHT is synthesized in the prostate from circulating testosterone by the action of the
enzyme5α-reductase, type 2. DHT can act in an
autocrine fashion on the stromal cells or in
paracrine fashion by diffusing into nearby
epithelial cells. In both of these cell types, DHT binds to nuclear
androgen receptors and signals the
transcription of
growth factors that are mitogenic to the epithelial and stromal cells. DHT is ten times more potent than testosterone because it dissociates from the androgen receptor more slowly. The importance of DHT in causing
nodular hyperplasia is supported by clinical observations in which an
inhibitor of 5α-reductase such as
finasteride is given to men with this condition. Therapy with a 5α-reductase inhibitor markedly reduces the DHT content of the prostate and, in turn, reduces prostate volume and BPH symptoms.[23][24]
Testosterone promotes prostate cell proliferation,[25] but relatively low levels of serum testosterone are found in patients with BPH.[26][27] One small study has shown that medical castration lowers the serum and prostate hormone levels unevenly, having less effect on testosterone and dihydrotestosterone levels in the prostate.[28]
Besides testosterone and DHT, other androgens are also known to play a crucial role in BPH development. C 21 11-oxygenated steroids (pregnanes) have been identified are precursors to 11-oxygenated androgens which are also potent agonists for the androgen receptor.[29] Specifically, steroids like
11β-hydroxyprogesterone and
11-ketoprogesterone can be converted to
11-ketodihydrotestosterone, an 11-oxo form of DHT with the same potency. These precursors have also been detected in tissue
biopsy samples from patients with BPH, as well as in their serum levels.[30][31][32] Besides that, androgens biosythnesized via a
backdoor pathway can contribute to the development of BPH.[30]
While there is some evidence that estrogen may play a role in the cause of BPH, this effect appears to be mediated mainly through local conversion of androgens to estrogen in the prostate tissue rather than a direct effect of estrogen itself.[33] In canine in vivo studies castration, which significantly reduced androgen levels but left estrogen levels unchanged, caused significant atrophy of the prostate.[34] Studies looking for a correlation between prostatic hyperplasia and serum estrogen levels in humans have generally shown none.[27][35]
In 2008, Gat et al. published evidence that BPH is caused by failure in the spermatic venous drainage system resulting in increased hydrostatic pressure and local testosterone levels elevated more than 100 fold above serum levels.[36] If confirmed, this mechanism explains why serum androgen levels do not seem to correlate with BPH and why giving exogenous testosterone would not make much difference.
Diet
Studies indicate that dietary patterns may affect development of BPH, but further research is needed to clarify any important relationship.[37] Studies from China suggest that greater protein intake may be a factor in development of BPH. Men older than 60 in rural areas had very low rates of clinical BPH, while men living in cities and consuming more animal protein had a higher incidence.[38][39] On the other hand, a study in Japanese-American men in Hawaii found a strong negative association with alcohol intake, but a weak positive association with beef intake.[40] In a large prospective cohort study in the US (the Health Professionals Follow-up Study), investigators reported modest associations between BPH (men with strong symptoms of BPH or surgically confirmed BPH) and total energy and protein, but not fat intake.[41] There is also epidemiological evidence linking BPH with
metabolic syndrome (concurrent
obesity, impaired glucose metabolism and
diabetes,
high triglyceride levels, high levels of low-density cholesterol, and
hypertension).[42]
Degeneration
Benign prostatic hyperplasia is an age-related disease. Misrepair-accumulation aging theory[43] suggests that development of benign prostatic hyperplasia is a consequence of
fibrosis and weakening of the muscular tissue in the prostate.[44] The muscular tissue is important in the functionality of the prostate, and provides the force for excreting the fluid produced by prostatic glands. However, repeated contractions and dilations of myofibers will unavoidably cause injuries and broken myofibers. Myofibers have a low potential for regeneration; therefore, collagen fibers need to be used to replace the broken myofibers. Such misrepairs make the muscular tissue weak in functioning, and the fluid secreted by glands cannot be excreted completely. Then, the accumulation of fluid in glands increases the resistance of muscular tissue during the movements of contractions and dilations, and more and more myofibers will be broken and replaced by collagen fibers.[45]
Pathophysiology
As men age, the enzymes
aromatase and
5-alpha reductase increase in activity. These enzymes are responsible for converting androgen hormones into
estrogen and
dihydrotestosterone, respectively. This metabolism of androgen hormones leads to a decrease in testosterone but increased levels of DHT and estrogen.
Both the glandular epithelial cells and the stromal cells (including muscular fibers) undergo hyperplasia in BPH.[2] Most sources agree that of the two tissues, stromal hyperplasia predominates, but the exact ratio of the two is unclear.[46]: 694
Anatomically the median and lateral lobes are usually enlarged, due to their highly glandular composition. The anterior lobe has little in the way of glandular tissue and is seldom enlarged. (Carcinoma of the prostate typically occurs in the posterior lobe – hence the ability to discern an irregular outline per rectal examination). The earliest microscopic signs of BPH usually begin between the age of 30 and 50 years old in the PUG, which is posterior to the proximal urethra.[46]: 694 In BPH, the majority of growth occurs in the transition zone (TZ) of the prostate.[46]: 694 In addition to these two classic areas, the peripheral zone (PZ) is also involved to a lesser extent.[46]: 695 Prostatic cancer typically occurs in the PZ. However, BPH nodules, usually from the TZ are often biopsied anyway to rule out cancer in the TZ.[46]: 695 BPH can be a progressive growth that in rare instances leads to exceptional enlargement.[47] In some males, the prostate enlargement exceeds 200 to 500 grams.[47] This condition has been defined as giant prostatic hyperplasia (GPH).[47]
Diagnosis
The clinical diagnosis of BPH is based on a history of LUTS (lower urinary tract symptoms), a digital rectal exam, and exclusion of other causes of similar signs and symptoms. The degree of LUTS does not necessarily correspond to the size of the prostate. An enlarged prostate gland on
rectal examination that is symmetric and smooth supports a diagnosis of BPH.[2] However, if the prostate gland feels asymmetrical, firm, or nodular, this raises concern for prostate cancer.[2]
Validated questionnaires such as the American Urological Association Symptom Index (AUA-SI), the
International Prostate Symptom Score (I-PSS), and more recently the UWIN score (urgency, weak stream, incomplete emptying, and nocturia) are useful aids to making the diagnosis of BPH and quantifying the severity of symptoms.[2][48][49]
Laboratory investigations
Urinalysis is typically performed when LUTS are present and BPH is suspected to evaluate for signs of a urinary tract infection,
glucose in the urine (suggestive of diabetes), or
protein in the urine (suggestive of kidney disease).[2] Bloodwork including
kidney function tests and
prostate specific antigen (PSA) are often ordered to evaluate for kidney damage and prostate cancer, respectively.[2] However, checking blood PSA levels for
prostate cancer screening is controversial and not necessarily indicated in every evaluation for BPH.[2] Benign prostatic hyperplasia and prostate cancer are both capable of increasing blood PSA levels and PSA elevation is unable to differentiate these two conditions well.[2] If PSA levels are checked and are high, then further investigation is warranted. Measures including PSA density, free PSA, rectal examination, and transrectal
ultrasonography may be helpful in determining whether a PSA increase is due to BPH or prostate cancer.[2]
Imaging and other investigations
Uroflowmetry is done to measure the rate of urine flow and total volume of urine voided when the subject is urinating.[50]
Abdominal ultrasound examination of the prostate and
kidneys is often performed to rule out
hydronephrosis and hydroureter. Incidentally, cysts, tumours, and stones may be found on ultrasound.
Post-void residual volume of more than 100 ml may indicate significant obstruction.[51] Prostate size of 30 cc or more indicates enlargement of the prostate.[52]
Prostatic calcification can be detected through transrectal ultrasound (TRUS). Calcification is due to solidification of prostatic secretions or calcified
corpora amylacea (
hyaline masses on the prostate gland). Calcification is also found in a variety of other conditions such as prostatitis,
chronic pelvic pain syndrome, and prostate cancer.[53][54] For those with elevated levels of PSA, TRUS guided biopsy is performed to take a sample of the prostate for investigation.[55] Although MRI is more accurate than TRUS in determining prostate volume, TRUS is less expensive and almost as accurate as MRI. Therefore, TRUS is still preferred to measure prostate volume.[56]
When treating and managing benign prostatic hyperplasia, the aim is to prevent complications related to the disease and improve or relieve symptoms.[57] Approaches used include lifestyle modifications, medications, catheterisation and surgery.
Lifestyle
Lifestyle alterations to address the symptoms of BPH include physical activity,[58] decreasing fluid intake before bedtime, moderating the consumption of alcohol and caffeine-containing products and following a timed voiding schedule.
Patients can also attempt to avoid products and medications with
anticholinergic properties that may exacerbate urinary retention symptoms of BPH, including
antihistamines,
decongestants,
opioids, and
tricyclic antidepressants; however, changes in medications should be done with input from a medical professional.[59]
Physical activity
Physical activity has been recommended as a treatment for urinary tract symptoms. A 2019 Cochrane review of six studies involving 652 men assessing the effects of physical activity alone, physical activity as a part of a self-management program, among others. However, the quality of evidence was very low and therefore it remains uncertain whether physical activity is helpful in men experiencing urinary symptoms caused by benign prostatic hyperplasia.[60]
Voiding position
Voiding position when urinating may influence urodynamic parameters (urinary flow rate, voiding time, and post-void residual volume).[61] A
meta-analysis found no differences between the standing and sitting positions for healthy males, but that, for elderly males with lower urinary tract symptoms, voiding in the sitting position-- [62]
decreased the post void residual volume;
increased the maximum urinary flow, comparable with pharmacological intervention; and
Selective α1-blockers are the most common choice for initial therapy.[64][65][66] They include
alfuzosin,[67][68]doxazosin,[69]silodosin,
tamsulosin,
terazosin, and
naftopidil.[57] They have a small to moderate benefit at improving symptoms.[70][57][71] Selective alpha-1 blockers are similar in effectiveness but have slightly different side effect profiles.[70][57][71] Alpha blockers relax smooth muscle in the prostate and the bladder neck, thus decreasing the blockage of urine flow. Common side effects of alpha blockers include
orthostatic hypotension (a head rush or dizzy spell when standing up or stretching),
ejaculation changes,
erectile dysfunction,[72] headaches, nasal congestion, and weakness. For men with
LUTS due to an enlarged prostate, the effects of naftopidil, tamsulosin and silodosin on urinary symptoms and quality of life may be similar.[57] Naftopidil and tamsulosin may have similar levels of unwanted sexual side effects but fewer unwanted side effects than silodosin.[57]
Tamsulosin and silodosin are selective α1 receptor blockers that preferentially bind to the α1A receptor in the prostate instead of the α1B receptor in the blood vessels. Less-selective α1 receptor blockers such as terazosin and doxazosin may lower blood pressure. The older, less selective α1-adrenergic blocker prazosin is not a first line choice for either
high blood pressure or prostatic hyperplasia; it is a choice for patients who present with both problems at the same time. The older, broadly non-selective alpha blocker medications such as
phenoxybenzamine are not recommended for control of BPH.[73] Non-selective alpha blockers such as terazosin and doxazosin may also require slow dose adjustments as they can lower blood pressure and cause
syncope (fainting) if the response to the medication is too strong.
5α-reductase inhibitors
The 5α-reductase inhibitors
finasteride and
dutasteride may also be used in people with BPH.[74] These medications inhibit the
5α-reductase enzyme, which, in turn, inhibits production of
DHT, a hormone responsible for enlarging the prostate. Effects may take longer to appear than alpha blockers, but they persist for many years.[75] When used together with alpha blockers, no benefit was reported in short-term trials, but in a longer-term study (3–4 years) there was a greater reduction in BPH progression to acute urinary retention and surgery than with either agent alone, especially in people with more severe symptoms and larger prostates.[76][77][78] Other trials have confirmed reductions in symptoms, within 6 months in one trial, an effect that was maintained after withdrawal of the alpha blocker.[77][79] Side effects include decreased
libido and ejaculatory or erectile dysfunction.[80][81] The 5α-reductase inhibitors are contraindicated in pregnant women because of their
teratogenicity due to interference with fetal testosterone metabolism, and as a precaution, pregnant women should not handle crushed or broken tablets.[82]
Phosphodiesterase inhibitors (PDE)
A 2018 Cochrane review of studies on men over 60 with moderate to severe
lower urinary tract symptoms analyzed the impacts of
phosphodiesterase inhibitors (PDE) in comparison to other drugs.[83] These drugs may improve urinary symptoms slightly and reduce urinary bother but may also cause more side effects compared to placebo. The evidence in this review found that there is probably no difference between PDE and
alpha blockers, however when used in combination they may provide a greater improvement in symptoms (with more side effects). PDE also likely improves symptoms when used in combination with
5-alpha reductase inhibitors.
Several phosphodiesterase-5 inhibitors are also effective, but may require multiple doses daily to maintain adequate urine flow.[84][85]Tadalafil, a phosphodiesterase-5 inhibitor, was considered then rejected by NICE in the UK for the treatment of symptoms associated with BPH.[86] In 2011, the U.S. Food and Drug Administration approved tadalafil to treat the signs and symptoms of benign prostatic hyperplasia, and for the treatment of BPH and erectile dysfunction (ED), when the conditions occur simultaneously.[87]
Intermittent
urinary catheterization is used to relieve the bladder in people with
urinary retention. Self-catheterization is an option in BPH when it is difficult or impossible to completely empty the bladder.[90]Urinary tract infection is the most common complication of intermittent catheterization.[91] Several techniques and types of catheter are available, including sterile (single-use) and clean (multiple use) catheters, but, based on current information, none is superior to others in reducing the incidence of urinary tract infection.[92]
Thulium laser transurethral vaporesection of the prostate (ThuVARP)
Photoselective vaporization of the prostate (PVP)
Aquablation therapy: a type of surgery using a water jet to remove prostatic tissue.
Minimally invasive procedures
Some less invasive procedures are available according to patients' preferences and co-morbidities. These are performed as
outpatient procedures with
local anesthesia.
Prostatic artery embolization: an endovascular procedure performed in
interventional radiology.[95] Through
catheters, embolic agents are released in the main branches of the prostatic artery, in order to induce a decrease in the size of the prostate gland, thus reducing the urinary symptoms.[96]
Water vapor thermal therapy (marketed as Rezum): This is a newer office procedure for removing prostate tissue using steam aimed at preserving sexual function.
Prostatic urethral lift (marketed as UroLift): This intervention consists of a system of a device and an implant designed to pull the prostatic lobe away from the urethra.[97]
Transurethral microwave thermotherapy (TUMT) is an outpatient procedure that is less invasive compared to surgery and involves using microwaves (heat) to shrink prostate tissue that is enlarged.[93]
Temporary implantable nitinol device (TIND and iTIND): is a device that is placed in the urethra that, when released, is expanded, reshaping the urethra and the bladder neck.[98]
Alternative medicine
While
herbal remedies are commonly used, a 2016 review found the herbs studied to be no better than
placebos.[99] Particularly, several reviews found that
saw palmetto extract, while one of the most commonly used, is no better than a placebo both in symptom relief and in decreasing prostate size.[100][101][102]
Epidemiology
Globally, benign prostatic hyperplasia affects about 210 million males as of 2010 (6% of the population).[104]
The prostate gets larger in most men as they get older. For a symptom-free man of 46 years, the risk of developing BPH over the next 30 years is 45%.
Incidence rates increase from 3 cases per 1000 man-years at age 45–49 years, to 38 cases per 1000 man-years by the age of 75–79 years. While the
prevalence rate is 2.7% for men aged 45–49, it increases to 24% by the age of 80 years.[105]
^Chang RT, Kirby R, Challacombe BJ (April 2012). "Is there a link between BPH and prostate cancer?". The Practitioner. 256 (1750): 13–6, 2.
PMID22792684.
^Lower urinary tract symptoms in men: management, NICE (National Institute for Health and Care Excellence)
^"Urge incontinence". MedlinePlus. US National Library of Medicine.
Archived from the original on 6 October 2015. Retrieved 26 October 2015.
^Sarma AV, Wei JT (July 2012). "Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms". The New England Journal of Medicine. 367 (3): 248–57.
doi:
10.1056/nejmcp1106637.
PMID22808960.
^Bartsch G, Rittmaster RS, Klocker H (April 2002). "Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia". World Journal of Urology. 19 (6): 413–25.
doi:
10.1007/s00345-002-0248-5.
PMID12022710.
S2CID3257666.
^Feldman BJ, Feldman D (October 2001). "The development of androgen-independent prostate cancer". Nature Reviews. Cancer. 1 (1): 34–45.
doi:
10.1038/35094009.
PMID11900250.
S2CID205020623.
^Lagiou P, Mantzoros CS, Tzonou A, Signorello LB, Lipworth L, Trichopoulos D (1997). "Serum steroids in relation to benign prostatic hyperplasia". Oncology. 54 (6): 497–501.
doi:
10.1159/000227609.
PMID9394847.
^
abRoberts RO, Jacobson DJ, Rhodes T, Klee GG, Leiber MM, Jacobsen SJ (October 2004). "Serum sex hormones and measures of benign prostatic hyperplasia". The Prostate. 61 (2): 124–31.
doi:
10.1002/pros.20080.
PMID15305335.
S2CID24288565.
^
abdu Toit T, Swart AC (2020). "The 11β-hydroxyandrostenedione pathway and C11-oxy C21 backdoor pathway are active in benign prostatic hyperplasia yielding 11keto-testosterone and 11keto-progesterone". The Journal of Steroid Biochemistry and Molecular Biology. 196: 105497.
doi:
10.1016/j.jsbmb.2019.105497.
PMID31626910.
S2CID204734045.
^Zhang SX, Yu B, Guo SL, Wang YW, Yin CK (February 2003). "[Comparison of incidence of BPH and related factors between urban and rural inhabitants in district of Wannan]". Zhonghua Nan Ke Xue = National Journal of Andrology. 9 (1): 45–7.
PMID12680332.
^Gu F (March 1997). "Changes in the prevalence of benign prostatic hyperplasia in China". Chinese Medical Journal. 110 (3): 163–6.
PMID9594331.
^Chyou PH, Nomura AM, Stemmermann GN, Hankin JH (1993). "A prospective study of alcohol, diet, and other lifestyle factors in relation to obstructive uropathy". The Prostate. 22 (3): 253–64.
doi:
10.1002/pros.2990220308.
PMID7683816.
S2CID32639108.
^Wang-Michelitsch J, Michelitsch T (2015). "Tissue fibrosis: a principal evidence for the central role of Misrepairs in aging".
arXiv:1503.01376 [
cs.DM].
^
abcdeWasserman NF (September 2006). "Benign prostatic hyperplasia: a review and ultrasound classification". Radiologic Clinics of North America. 44 (5): 689–710, viii.
doi:
10.1016/j.rcl.2006.07.005.
PMID17030221.
^Eid K, Krughoff K, Stoimenova D, Smith D, Phillips J, O'Donnell C, Barqawi A (January 2014). "Validation of the Urgency, Weak stream, Incomplete emptying, and Nocturia (UWIN) score compared with the American Urological Association Symptoms Score in assessing lower urinary tract symptoms in the clinical setting". Urology. 83 (1): 181–5.
doi:
10.1016/j.urology.2013.08.039.
PMID24139351.
^Lee JS, Chung BH (2007). "Transrectal ultrasound versus magnetic resonance imaging in the estimation of prostate volume as compared with radical prostatectomy specimens". Urologia Internationalis. 78 (4): 323–327.
doi:
10.1159/000100836.
PMID17495490.
S2CID10731245.
^Silva J, Silva CM, Cruz F (January 2014). "Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?". Current Opinion in Urology. 24 (1): 21–8.
doi:
10.1097/mou.0000000000000007.
PMID24231531.
S2CID40954757.
^Roehrborn CG, Nuckolls JG, Wei JT, Steers W, et al. (BPH Registry and Patient Survey Steering Committee) (October 2007). "The benign prostatic hyperplasia registry and patient survey: study design, methods and patient baseline characteristics". BJU International. 100 (4): 813–9.
doi:
10.1111/j.1464-410X.2007.07061.x.
hdl:2027.42/73286.
PMID17822462.
S2CID21001077.
^Hutchison A, Farmer R, Verhamme K, Berges R, Navarrete RV (January 2007). "The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries". European Urology. 51 (1): 207–15, discussion 215–6.
doi:
10.1016/j.eururo.2006.06.012.
PMID16846678.
^MacDonald R, Wilt TJ (October 2005). "Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects". Urology. 66 (4): 780–8.
doi:
10.1016/j.urology.2005.05.001.
PMID16230138.
^Roehrborn CG (December 2001). "Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial". Urology. 58 (6): 953–9.
doi:
10.1016/S0090-4295(01)01448-0.
PMID11744466.
^
abWilt TJ, Mac Donald R, Rutks I (2003). Wilt T (ed.). "Tamsulosin for benign prostatic hyperplasia". The Cochrane Database of Systematic Reviews (1): CD002081.
doi:
10.1002/14651858.CD002081.
PMID12535426.
^
abDjavan B, Marberger M (1999). "A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction". European Urology. 36 (1): 1–13.
doi:
10.1159/000019919.
PMID10364649.
S2CID73366414.
^Roehrborn CG, Bruskewitz R, Nickel JC, McConnell JD, Saltzman B, Gittelman MC, et al. (Proscar Long-Term Efficacy Safety Study Group) (March 2004). "Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia". The Journal of Urology. 171 (3): 1194–8.
doi:
10.1097/01.ju.0000112918.74410.94.
PMID14767299.
^Roehrborn CG, Barkin J, Tubaro A, Emberton M, Wilson TH, Brotherton BJ, Castro R (April 2014). "Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study". BJU International. 113 (4): 623–35.
doi:
10.1111/bju.12500.
PMID24127818.
S2CID38243275.
^Kaplan SA, McConnell JD, Roehrborn CG, Meehan AG, Lee MW, Noble WR, et al. (Medical Therapy of Prostatic Symptoms (MTOPS) Research Group) (January 2006). "Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater". The Journal of Urology. 175 (1): 217–20, discussion 220–1.
doi:
10.1016/S0022-5347(05)00041-8.
PMID16406915.
^Barkin J, Guimarães M, Jacobi G, Pushkar D, Taylor S, van Vierssen Trip OB (October 2003). "Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride". European Urology. 44 (4): 461–6.
doi:
10.1016/s0302-2838(03)00367-1.
PMID14499682.
^Gacci M, Ficarra V, Sebastianelli A, Corona G, Serni S, Shariat SF, et al. (June 2014). "Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis". The Journal of Sexual Medicine. 11 (6): 1554–66.
doi:
10.1111/jsm.12525.
PMID24708055.
^Wang Y, Bao Y, Liu J, Duan L, Cui Y (January 2018). "Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis". Lower Urinary Tract Symptoms. 10 (1): 84–92.
doi:
10.1111/luts.12144.
PMID29341503.
S2CID23929021.
^Kuang M, Vu A, Athreya S (May 2017). "A Systematic Review of Prostatic Artery Embolization in the Treatment of Symptomatic Benign Prostatic Hyperplasia". CardioVascular and Interventional Radiology. 40 (5): 655–663.
doi:
10.1007/s00270-016-1539-3.
PMID28032133.
S2CID12154537.
^Pisco J, Bilhim T, Pinheiro LC, Fernandes L, Pereira J, Costa NV, et al. (May 2016). "Prostate Embolization as an Alternative to Open Surgery in Patients with Large Prostate and Moderate to Severe Lower Urinary Tract Symptoms". Journal of Vascular and Interventional Radiology. 27 (5): 700–8.
doi:
10.1016/j.jvir.2016.01.138.
PMID27019980.
^Verhamme KM, Dieleman JP, Bleumink GS, van der Lei J, Sturkenboom MC, Artibani W, et al. (Triumph Pan European Expert Panel) (October 2002). "Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care--the Triumph project". European Urology. 42 (4): 323–8.
doi:
10.1016/S0302-2838(02)00354-8.
PMID12361895.